Thor Therapeutics Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Series A
- Investors
-
7
Thor Therapeutics General Information
Description
Developer of biopharmaceutical therapeutics designed to treat cancer cachexia and metabolic dysfunction. The company combines modern genetic, molecular biology, and structural biology techniques coupled with computational expertise to efficiently validate novel biological and chemical therapeutics across various targets, including membrane receptors, hormones, and ligand-receptor interactions, enabling the health industry to develop preclinical monoclonal antibody and antisense oligonucleotide candidates for novel therapeutic targets.
Contact Information
Website
thortherapeutics.comCorporate Office
- A203, Startup Square, 40, Geumto-ro 80beon-gil
- Sujeong-gu 13453
- Seongnam, Gyeonggi-do
- South Korea
Corporate Office
- A203, Startup Square, 40, Geumto-ro 80beon-gil
- Sujeong-gu 13453
- Seongnam, Gyeonggi-do
- South Korea
Thor Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A) | 30-Oct-2026 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 23-Mar-2023 | Completed | Pre-Clinical Trials | |||
| 1. Seed Round | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Thor Therapeutics Patents
Thor Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025274035-A1 | Monoclonal antibody targeting gfral and use thereof | Pending | 24-May-2024 | ||
| WO-2025244462-A1 | Monoclonal antibody targeting gfral and use thereof | Pending | 24-May-2024 | ||
| EP-4653531-A1 | Antisense oligomers targeting gfral and use thereof | Pending | 20-Jan-2023 | ||
| US-20260218200-A1 | Antisense oligomers targeting gfral and use thereof | Pending | 20-Jan-2023 | ||
| WO-2024155160-A1 | Antisense oligomers targeting gfral and use thereof | Inactive | 20-Jan-2023 | A61P35/00 |
Thor Therapeutics Signals
Thor Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alteogen | Corporation | Minority | ||
| BetterLuck Partners | Corporation | Minority | ||
| BioHealthcare Association | Corporation | Minority | ||
| The Iroun Partners | Venture Capital | Minority | ||
| Tech Incubator Program for Startup | Accelerator/Incubator |
Thor Therapeutics FAQs
-
When was Thor Therapeutics founded?
Thor Therapeutics was founded in 2022.
-
Where is Thor Therapeutics headquartered?
Thor Therapeutics is headquartered in Seongnam, South Korea.
-
What is the size of Thor Therapeutics?
Thor Therapeutics has 3 total employees.
-
What industry is Thor Therapeutics in?
Thor Therapeutics’s primary industry is Drug Discovery.
-
Is Thor Therapeutics a private or public company?
Thor Therapeutics is a Private company.
-
What is Thor Therapeutics’s current revenue?
The current revenue for Thor Therapeutics is .
-
Who are Thor Therapeutics’s investors?
Alteogen, BetterLuck Partners, BioHealthcare Association, The Iroun Partners, and Tech Incubator Program for Startup are 5 of 7 investors who have invested in Thor Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process